Curated News
By: NewsRamp Editorial Staff
March 06, 2026
Tonix Pharmaceuticals Publishes Key TONMYA Study for Fibromyalgia Treatment
TLDR
- Tonix Pharmaceuticals gains a competitive edge with TONMYA's FDA approval for fibromyalgia, offering a first-in-class non-opioid analgesic that bypasses liver metabolism for faster relief.
- TONMYA's sublingual formulation uses a basifying agent for rapid transmucosal absorption, increasing parent drug exposure during sleep while reducing metabolite levels to improve tolerability and durability.
- This new fibromyalgia treatment provides millions of chronic pain sufferers with a non-opioid option, potentially improving daily quality of life and reducing medication side effects.
- Tonix's TONMYA represents the first new FDA-approved fibromyalgia drug in over 15 years, using innovative sublingual technology to deliver pain relief while you sleep.
Impact - Why it Matters
This news matters because it represents a significant advancement in chronic pain management, particularly for the millions of adults suffering from fibromyalgia who have had limited treatment options for over 15 years. The FDA approval and published research on TONMYA's novel sublingual formulation offer a non-opioid alternative that could transform patient care by providing durable pain relief with potentially better tolerability. For investors, it highlights Tonix's growing commercial presence and diverse pipeline across multiple therapeutic areas, while for the medical community, it provides valuable pharmacokinetic data supporting clinical use. The broader implications include potential applications of the technology for other CNS disorders and the company's contributions to national security through its DoD-funded infectious disease research.
Summary
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial biotechnology company, has announced a significant scientific milestone with the publication of peer-reviewed research in Clinical Pharmacology in Drug Development. The paper details the pharmacokinetics of TNX-102 SL, the sublingual formulation of cyclobenzaprine HCl marketed as TONMYA™, which received FDA approval on August 15, 2025, for treating fibromyalgia in adults. This first-in-class, non-opioid analgesic represents the first new prescription medicine for fibromyalgia in over 15 years, offering hope to millions suffering from this chronic pain condition. The study highlights TONMYA's proprietary basifying agent that enables rapid transmucosal absorption, bypassing first-pass hepatic metabolism to increase parent drug exposure during sleep while reducing exposure to the long-acting metabolite norcyclobenzaprine.
The research, published in the journal of the American College of Clinical Pharmacology, demonstrates how this innovative formulation supports durable analgesic benefits with improved tolerability. For those interested in the complete details, the full press release is available through BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN that delivers comprehensive distribution services for biotechnology and biomedical sciences news. Tonix Pharmaceuticals, which also markets Zembrace® SymTouch® and Tosymra® for acute migraine, maintains a diverse development portfolio focused on central nervous system disorders, immunology, immuno-oncology, rare diseases, and infectious diseases, including promising candidates like TNX-1500 for autoimmune diseases and TNX-801 for mpox and smallpox.
Beyond TONMYA, Tonix's pipeline includes TNX-102 SL being developed for acute stress reaction and major depressive disorder, TNX-2900 for Prader-Willi syndrome, and TNX-4800 for Lyme disease prevention. The company's infectious disease research facility in Frederick, Maryland, supports these efforts, including work on TNX-4200 under a U.S. Department of Defense contract worth up to $34 million. Investors can find the latest updates relating to TNXP in the company's newsroom, while BioMedWire continues to serve as a vital platform for disseminating breaking news and insightful content in the life sciences sector, helping companies reach investors, journalists, and the general public through enhanced press release distribution and social media networks.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix Pharmaceuticals Publishes Key TONMYA Study for Fibromyalgia Treatment
